EHA 2022 | Strategies to overcome resistance to HMAs
In this video, Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China discusses the mechanisms of resistance to hypomethylating agents (HMA) and the several strategies available to overcome this resistance. For example, Dr Gill describes how IDH1 or IDH2 mutations may confer resistance and how these mutations may be targeted with ivosidenib. Dr Gill also comments on immune dysregulation MDS and highlights the potential of targeting TIM-3 with monoclonal antibodies such as sabatolimab. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Oncology – honoraria, consultancies; Celgene/bms – research grant, honoraria, consultancies; PharmaEssentia – research grant; Abbvie – honoraria, consultancies; Takeda – honoraria; Pfizer Oncology – honoraria, consultant
